Russian Scientists Develop Two World-First Gene Therapy Drugs Against Aging
The Russian Ministry of Science and Higher Education has unveiled plans to create unique drugs: one blocks the RAGE gene, which triggers cellular aging, and the other, based on exosomes from young cells, targets sarcopenia—age-related muscle loss. Research is conducted at the Institute of Biology of Aging.
On the Path to Controlled Longevity: How Russia is Developing the World's First Gene Therapy Against Aging
Introduction
"The RAGE gene is a receptor whose activation triggers cellular aging; blocking this gene, on the contrary, can extend a cell's youth." These words from Denis Sekirinsky, Deputy Minister of Science and Higher Education of the Russian Federation, spoken on April 23, 2026, at a conference in Saransk, sound like a quote from a science fiction novel. But behind them lies a real and ambitious goal: creating the world's first gene therapy drug that specifically blocks the mechanisms of cellular aging.
Simultaneously, Russian scientists are working on another unique product—a drug against sarcopenia (age-related muscle loss) based on exosomes from young cells. Both developments are being carried out by the Institute of Biology of Aging and Medicine in partnership with the Petrovsky National Research Center of Surgery under the national project "New Technologies for Health Preservation."
These initiatives mark not just another step in gerontology. They represent a fundamentally new approach to aging—not as an inevitable process that can only be managed with symptomatic treatment "crutches," but as a biological mechanism that can be modified, slowed, and possibly reversed.
Event Details and Timeline
Announcement at the Saransk Conference
On April 23–24, 2026, an all-Russian off-site conference was held in Saransk as part of the regional movement "For Healthy Longevity Medicine." The event was attended by politicians, public figures, leading healthcare experts, and over 300 doctors from across the country.
It was at this conference that Denis Sekirinsky, Deputy Minister of Science and Higher Education of the Russian Federation, officially presented two ambitious developments in gene therapy for aging.
First Direction: Blocking the RAGE Gene
Mechanism of Action: The RAGE gene (Receptor for Advanced Glycation End Products) encodes a receptor protein whose activation triggers a cascade of inflammatory reactions and accelerates cellular aging. Blocking this gene could theoretically slow age-related changes at the cellular level.
Development Status: Researchers at the Institute of Biology of Aging and Medicine have set "an ambitious goal—to develop the world's first gene therapy drug that specifically blocks the aforementioned receptor." The work relies on cutting-edge genetic technologies and is considered one of the most promising directions in the fight against aging.
Second Direction: Exosome Therapy for Sarcopenia
What is Sarcopenia: It is a progressive generalized loss of muscle mass and strength characteristic of older age. A key feature is that in later stages, muscle recovery through exercise is no longer possible.
Role of Exosomes: Exosomes are tiny extracellular vesicles that cells use for intercellular communication. They carry proteins, lipids, and genetic material, influencing the metabolism of recipient cells.
Experimental Confirmation: In 2025, scientists at the Petrovsky National Research Center of Surgery conducted experimental studies that proved:
- Transplanting exosomes from aging cells to young cells leads to a multiple-fold increase in inflammation and accelerated aging of young cells.
- Conversely, transplanting exosomes from young cells to aging cells triggers rejuvenation processes.
Konstantin Kotenko, Director of the Petrovsky National Research Center of Surgery, confirmed: "We have obtained interesting preliminary results showing that exosomes can both accelerate the aging of young cells and rejuvenate aging cells."
Development Goal: Creating the world's first drug for the prevention and treatment of sarcopenia, which will help restore motor activity in older people.
Strategic Context
These developments fit into a broader state strategy. In 2025, Deputy Prime Minister Tatyana Golikova stated at the forum "Russia and the World: Trends in Healthy Longevity" that Russian scientists plan to develop drugs that restore aging cells, as well as biomedical cell products for treating brain and spinal cord injuries, wounds, and burns, in 2028–2030.
Impact and Significance
For Medical Science: A Paradigm Shift
Traditional gerontology has long been a descriptive science: it studied how and why aging occurs but did not offer tools to modify it. Recent decades have seen a breakthrough in understanding the molecular mechanisms of aging.
The development of a gene therapy drug against the RAGE gene represents a transition from "observation" to "intervention." This is not vitamins and antioxidants promising to "slow aging" with questionable evidence. It is targeted editing of gene expression responsible for one of the key pathways of aging.
As for the exosome approach, it is also a cutting-edge direction in global science. In a review article published in the Journal of Cachexia, Sarcopenia and Muscle (2020), international researchers noted: "We suggest that exosomes may be a potential research direction for sarcopenia in the future." Russian scientists are now trying to turn this suggestion into a real therapeutic product.
For Society: Questions and Hopes
State Duma deputy Nina Ostanina, commenting on the development news, raised an important ethical question: "Who needs such years if there is no quality of life?"
She gave a poignant example: when she visited a hundred-year-old grandmother with good memory but bedridden, the grandmother answered the question about her wish: "I wish I could die sooner, dear."
This comment perfectly captures the essence of the problem that developers of geroprotectors must solve. Extending life itself is not the goal. The goal is extending healthy, active life (healthspan), not just life at any cost.
Sarcopenia is a vivid example of this approach. Loss of muscle mass in older people leads to falls, fractures, loss of independence, and bedriddenness. A drug that can prevent or reverse this process would radically change the quality of life for millions.
For the Industry: New Horizons and Challenges
Both developments are positioned as "world-first." This gives Russia an opportunity to take a leading position in the emerging field of "gerontological gene therapy"—a niche that could become one of the most commercially significant in pharmaceuticals in the coming decades.
However, the path from laboratory research to drug registration is long. Even the most optimistic forecasts, voiced by Tatyana Golikova, place the appearance of drugs that restore aging cells in 2028–2030. Ahead lie preclinical studies, clinical trial phases, and safety issues (especially for gene therapy drugs, which carry risks of oncogenesis and off-target editing).
Reactions of Key Players
The Russian Ministry of Science and Higher Education is actively promoting the initiative. Denis Sekirinsky not only announced the developments at the Saransk conference but also emphasized their strategic importance: the work is being carried out under the national project "New Technologies for Health Preservation."
The scientific community received the news as confirmation of a long-term strategy in gerontology. Konstantin Kotenko, Director of the Petrovsky National Research Center of Surgery, previously shared details about the experimental results that formed the basis of the exosome direction.
Political and public discourse is more complex. Nina Ostanina (head of the State Duma Committee on Family Protection) expressed skepticism, pointing out the dissonance between attempts to create a "pill for old age" and the current social problems of the elderly: lack of transportation in rural areas, insufficient care for lonely seniors.
"Simultaneously with the invention of such drugs for a long life, we must also take care to create social conditions for those who will live long," Ostanina concluded. This remark reflects an important public demand: technological progress in medicine must go hand in hand with the development of a long-term care system and social support.
International perspective: It is worth noting that research on exosomes as a potential tool against sarcopenia is also being conducted abroad. However, Russian scientists claim to create the world's first drug—that is, to bring the technology to the stage of a finished medicinal product.
Forecast and Conclusions
The announcement of the development of two world-first gene therapy drugs against aging is both an encouraging news and a reminder of the distance that remains to be covered.
Short-term prospects (2026–2028):
- Continuation of preclinical studies of exosome therapy and its transition to clinical trials.
- Expansion of fundamental research on the RAGE gene, clarification of blocking mechanisms.
- Assessment of safety and efficacy in animal models before moving to humans.
Long-term questions (2028–2035):
- Will these drugs pass all stages of clinical trials and obtain registration?
- What will be the safety profile of long-term gene modulation?
- What will be the cost of therapy—and will it be accessible to those who need it?
Main conclusion:
Russian science is betting on one of the most promising but also most challenging areas of modern medicine—modifying aging processes at the genetic and cellular level. The success of these developments could change not only medicine but also the very concept of the limits of human life.
However, as Nina Ostanina rightly noted, technological breakthroughs should not overshadow social problems. Increasing life expectancy without ensuring its quality is a utopia. Therapy that can delay sarcopenia and preserve muscle strength in old age is precisely the answer to the demand for quality longevity.
There is another aspect: the very formulation of the task to "block the aging gene" is a bold step that attracts attention and investment in fundamental aging science. Even if the first drug does not reach pharmacies, research on the RAGE gene and exosomes will expand our understanding of aging biology and open other therapeutic windows.
Russia has entered the race for a "cure for old age." We will not know the results of this race until the end of the decade. But one thing is clear now: aging is no longer perceived as something inevitable and beyond medical intervention. And that, perhaps, is the most important change.
— Editorial Team
